Q1 Earnings Forecast for Neurogene Issued By HC Wainwright

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Neurogene in a research report issued on Tuesday, March 25th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.85) for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.98) EPS and FY2025 earnings at ($3.68) EPS.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.05. The company had revenue of $0.93 million during the quarter.

Separately, William Blair reiterated an “outperform” rating on shares of Neurogene in a research report on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $59.80.

Neurogene Stock Up 13.7 %

NGNE stock opened at $16.14 on Thursday. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49. The company has a market cap of $239.76 million, a PE ratio of -3.78 and a beta of 1.01. The business’s 50-day simple moving average is $16.97 and its 200 day simple moving average is $29.06.

Insider Transactions at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.92% of the stock is currently owned by insiders.

Institutional Trading of Neurogene

Large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in Neurogene by 18.7% during the 4th quarter. Wellington Management Group LLP now owns 21,717 shares of the company’s stock worth $496,000 after acquiring an additional 3,427 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of Neurogene in the fourth quarter valued at $1,829,000. Squarepoint Ops LLC raised its holdings in shares of Neurogene by 250.0% in the fourth quarter. Squarepoint Ops LLC now owns 17,431 shares of the company’s stock valued at $398,000 after buying an additional 12,451 shares during the last quarter. Two Sigma Investments LP acquired a new position in Neurogene during the 4th quarter worth about $472,000. Finally, RTW Investments LP grew its holdings in Neurogene by 18.9% during the 4th quarter. RTW Investments LP now owns 1,350,256 shares of the company’s stock worth $30,867,000 after acquiring an additional 215,000 shares during the last quarter. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.